Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proliferative Diabetic Retinopathy (PDR) - Overview
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
Antisense Therapeutics Ltd
Boehringer Ingelheim Intertiol GmbH
Generium
Kubota Vision Inc
Kuur Therapeutics Ltd
Oxurion NV
Protheragen Inc
Ribomic Inc
Proliferative Diabetic Retinopathy (PDR) - Drug Profiles
AR-13503 SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-764524 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brolucizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-687 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects
Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones
Featured News & Press Releases
May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Ltd, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Generium, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kubota Vision Inc, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kuur Therapeutics Ltd, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Oxurion NV, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Protheragen Inc, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc, H2 2020
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2020